CSL Limited Annual Report 2022/23 30 CSL’s $2 billion-plus capital investment in Australia includes CSL Melbourne, a next-generation cell-based influenza vaccine manufacturing facility for CSL Seqirus in Tullamarine, Australia and also a Plasma Fractionation Facility in Broadmeadows, Australia.
RkJQdWJsaXNoZXIy MjE2NDg3